Environmental Geotechnics: Challenges and Opportunities in the Post COVID-19 World von Tang, C-S, Paleologos, EK, Vitone, C, Du, Y-J, Li, J-S, Jiang, N-J, Deng, Y-F, Chu, J, Shen, Z, Koda, E, Dominijanni, A, Fei, X, Vaverková, MD, Osiński, P, Chen, X, Asadi, A, Takeuchi, MRH, Bo, MW, Abuel-Naga, H, Leong, E-C, Farid, A, Baser, T, O’Kelly, BC, Jha, B, Goli, VSNS, Singh, DN

Volltext bestellen

A Review of the Occurrence and Causes for Wildfires and Their Impacts on the Geoenvironment von Farid, Arvin, Alam, Md Khorshed, Goli, Venkata Siva Naga Sai, Akin, Idil Deniz, Akinleye, Taiwo, Chen, Xiaohui, Cheng, Qing, Cleall, Peter, Cuomo, Sabatino, Foresta, Vito, Ge, Shangqi, Iervolino, Luca, Iradukunda, Pierrette, Luce, Charles H., Koda, Eugeniusz, Mickovski, Slobodan B., O’Kelly, Brendan C., Paleologos, Evan K., Peduto, Dario, Ricketts, Evan John, Sadegh, Mojtaba, Sarris, Theo S., Singh, Devendra N., Singh, Prithvendra, Tang, Chao-Sheng, Tardio, Guillermo, Vaverková, Magdalena Daria, Veneris, Max, Winkler, Jan

Volltext

Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High Risk Hypercholesterolemic Patients Stratified by Previous Statin Treatment Potency von Farnier, Michael, MD, Viigimaa, Margus, Vaverkova, Helena, Averna, Maurizio, Missault, Luc, Dong, Qian, Shah, Arvind, Hanson, Mary E, Brudi, Philippe

Volltext

Switching from Statin Monotherapy to EZE/Simva or Rosuva Modifies Apo B, LDL-C, and non-HDL-C Correlations in Patients at High Risk of Coronary Disease von Brudi, Philippe, MD, Vaverkova, Helena, Farnier, Michael, Dong, Qian, Johnson-Levonas, Amy O, Shah, Arvind

Volltext

Switching from Any Statin Brand to Ezetimibe/Simvastatin 10/20 mg is More Effective at Lowering Plasma Lipids Compared with Rosuvastatin 10 mg von Brudi, Philippe, MD, Averna, Maurizio, Missault, Luc, Farnier, Michael, Vaverkova, Helena, Viigimaa, Margus, Dong, Qian, Shah, Arvind, Taggart, William, Johnson-Levonas, Amy

Volltext

Efficacy of Switching from Statin Monotherapy to Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients Analyzed by Baseline LDL-C von Brudi, Philippe, MD, Averna, Maurizio, Farnier, Michael, Missault, Luc, Vaverkova, Helena, Viigimaa, Margus, Dong, Qian, Shah, Arvind, Taggart, William, Johnson-Levonas, Amy O

Volltext